Sökning: "liver toxicity"
Visar resultat 11 - 15 av 91 avhandlingar innehållade orden liver toxicity.
11. Comparative study of Radiation Therapy of Targets in the Upper Abdomen with Photon- or Scanned Proton-beams
Sammanfattning : Recently, there has been an increase in the number of proton beam therapy (PBT) centers operating worldwide. For certain cases, proton beams have been shown to provide dosimetric and radiobiological advantages when used for cancer treatment, compared to the regular photon-beam based treatments. LÄS MER
12. Human liver in vitro models for evaluation of drug metabolism and disposition
Sammanfattning : The administrated dose of a drug is adjusted to give a therapeutic effect in patients without causing side-effects or toxicity. Cytochrome P450 (P450) and UDP-glucuronosyltransferase (UGT) enzymes, uptake and efflux transporters and nuclear receptors regulating these enzymes, expressed in the liver and in other tissues, are all important players in drug metabolism, disposition and elimination. LÄS MER
13. Zebrafish as a model to study the neuroendocrine system and toxicity of endocrine disruptors
Sammanfattning : Zebrafish is a popular vertebrate model system to study development and perform genetic analysis. It offers numerous advantages such as small size, short generation time, high fecundity, rapid and ex utero development of embryos and optically transparent embryos. LÄS MER
14. Adrenocorticolysis Induced by 3-MeSO2-DDE : Mechanisms of Action, Kinetics and Species Differences
Sammanfattning : The DDT metabolite 3-methylsulphonyl-DDE (3-MeSO2-DDE) induces cell death specifically in the adrenal cortex of mice after a cytochrome P45011B1 (CYP11B1)-catalysed bioactivation. This substance is not only an environmental pollutant, but also a suggested lead compound for an improved chemotherapy of adrenocortical carcinoma (ACC). LÄS MER
15. Hepatic 3D spheroids as a model system for drug-induced liver injury and cytochrome P450 induction
Sammanfattning : Drug-induced liver injury (DILI) is a major cause of post-marketing drug withdrawals and restricted-use warnings. In addition, unexpected adverse hepatic drug reactions occurring in the clinical phases of development are a major reason for drug attrition. LÄS MER